A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis

References

• Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi: 10.1016/S0140-6736(19)32989-7
   PubMed Web of Science ®Google Scholar
• Tindal EW, Armstead BE, Monaghan SF, et al. Emerging therapeutic targets for sepsis. Expert Opin Ther Targets. 2021;25(3):175–189. doi: 10.1080/14728222.2021.1897107
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–2088. doi: 10.1126/science.282.5396.2085
   PubMed Web of Science ®Google Scholar
• Ohto U, Ishida H, Shibata T, et al. Toll-like receptor 9 contains two DNA binding sites that function cooperatively to promote receptor dimerization and activation. Immunity. 2018;48(4):649–658.e4. doi: 10.1016/j.immuni.2018.03.013
   PubMed Web of Science ®Google Scholar
• Hailman E, Lichenstein HS, Wurfel MM, et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179(1):269–277. doi: 10.1084/jem.179.1.269
   PubMed Web of Science ®Google Scholar
• Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249(4975):1431–1433. doi: 10.1126/science.1698311
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330(6149):662–664. doi: 10.1038/330662a0
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–2147. doi: 10.1182/blood.V87.6.2095.bloodjournal8762095
   PubMed Web of Science ®Google Scholar
• Heinzel FP. The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol. 1990;145(9):2920–2924. doi: 10.4049/jimmunol.145.9.2920
   PubMed Web of Science ®Google Scholar
• Ramadori G, Sipe JD, Dinarello CA, et al. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med. 1985;162(3):930–942. doi: 10.1084/jem.162.3.930
   PubMed Web of Science ®Google Scholar
• Sandri S, Rodriguez D, Gomes E, et al. Is serum amyloid a an endogenous TLR4 agonist? J Leukocyte Biol. 2008;83(5):1174–1180. doi: 10.1189/jlb.0407203
   PubMed Web of Science ®Google Scholar
• Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis [see comments]. Nat Med. 2000;6(6):643–651. doi: 10.1038/76216
   PubMed Web of Science ®Google Scholar
• Li W, Bao G, Chen W, et al. Connexin 43 hemichannel as a novel mediator of sterile and infectious inflammatory diseases. Sci Rep. 2018;8(1):166–18452. doi: 10.1038/s41598-017-18452-1
   PubMedGoogle Scholar
• Chen W, Zhu S, Wang Y, et al. Enhanced macrophage pannexin 1 expression and hemichannel activation exacerbates lethal experimental sepsis. Sci Rep. 2019;9(1):160–37232. doi: 10.1038/s41598-018-37232-z
   PubMedGoogle Scholar
• Zhu S, Wang Y, Chen W, et al. High-Density Lipoprotein (HDL) Counter-Regulates Serum Amyloid a (SAA)-induced sPLA2-IIE and sPLA2-V expression in macrophages. Plos One. 2016;11(11):e0167468. doi: 10.1371/journal.pone.0167468
   PubMed Web of Science ®Google Scholar
• Li W, Zhu S, Li J, et al. Serum amyloid a stimulates PKR expression and HMGB1 release possibly through TLR4/RAGE receptors. Mol Med. 2015;21(1):515–525. doi: 10.2119/molmed.2015.00109
   PubMedGoogle Scholar
• Zhu CS, Qiang X, Chen W, et al. Identification of procathepsin L (Pcts-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis. Sci Adv. 2023;9(5):eadf4313. doi: 10.1126/sciadv.adf4313
   PubMed Web of Science ®Google Scholar
• Johns EW. History,definitions and problems. In: Johns E, editor. The HMG chromosomal proteins. London: Academic Press Inc. (London) Ltd; 1982. p. 1–8. doi: 10.1016/B978-0-12-386050-7.50006-X.
   Google Scholar
• Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci. 2001;26(3):152–153. doi: 10.1016/S0968-0004(00)01777-1
   PubMed Web of Science ®Google Scholar
• Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19(8):5237–5246. doi: 10.1128/MCB.19.8.5237
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–251. doi: 10.1126/science.285.5425.248.
   PubMed Web of Science ®Google Scholar
• Yang K, Fan M, Wang X, et al. Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis. Cell Death Differ. 2022;29(1):133–146. doi: 10.1038/s41418-021-00841-9
   PubMed Web of Science ®Google Scholar
• Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A. 2014;111(8):3068–3073. doi: 10.1073/pnas.1316925111
   PubMed Web of Science ®Google Scholar
• Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006;177(11):7889–7897. doi: 10.4049/jimmunol.177.11.7889
   PubMed Web of Science ®Google Scholar
• Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-Dependent Mechanism. J Immunol. 2003;170(7):3890–3897. doi: 10.4049/jimmunol.170.7.3890
   PubMed Web of Science ®Google Scholar
• Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002;3(10):955–1001. doi: 10.1093/embo-reports/kvf198
   Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J. 2003;22(20):5551–5560. doi: 10.1093/emboj/cdg516
   PubMed Web of Science ®Google Scholar
• Garcia de Durango CR, Monteiro MN, Bijnsdorp IV, et al. Lipopolysaccharide-regulated secretion of soluble and vesicle-based proteins from a panel of colorectal cancer cell lines. Proteomics Clin Appl. 2021;15(2–3):e1900119. doi: 10.1002/prca.201900119
   PubMed Web of Science ®Google Scholar
• Volchuk A, Ye A, Chi L, et al. Indirect regulation of HMGB1 release by gasdermin D. Nat Commun. 2020;11(1):4561–18443. doi: 10.1038/s41467-020-18443-3
   PubMed Web of Science ®Google Scholar
• Hagar JA, Powell DA, Aachoui Y, et al. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science. 2013;341(6151):1250–1253. doi: 10.1126/science.1240988
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Sarkar A, Vande WL, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol. 2010;185(7):4385–4392. doi: 10.4049/jimmunol.1000803
   PubMed Web of Science ®Google Scholar
• Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 2012;488(7413):670–674. doi: 10.1038/nature11290
   PubMed Web of Science ®Google Scholar
• Vanaja SK, Russo AJ, Behl B, et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation. Cell. 2016;165(5):1106–1119. doi: 10.1016/j.cell.2016.04.015
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell. 2012;150(3):606–619. doi: 10.1016/j.cell.2012.07.007
   PubMed Web of Science ®Google Scholar
• Aachoui Y, Kajiwara Y, Leaf IA, et al. Canonical inflammasomes drive IFN-Î3 to prime caspase-11 in defense against a cytosol-invasive bacterium. Cell Host Microbe. 2015;18(3):320–332. doi: 10.1016/j.chom.2015.07.016
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SJ, Lee IS, et al. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol. 2009;182(4):2458–2466. doi: 10.4049/jimmunol.0801364
   PubMed Web of Science ®Google Scholar
• Yang X, Cheng X, Tang Y, et al. The role of type 1 interferons in coagulation induced by gram-negative bacteria. Blood. 2020;135(14):1087–1100. doi: 10.1182/blood.2019002282
   PubMed Web of Science ®Google Scholar
• Niemi K, Teirila L, Lappalainen J, et al. Serum amyloid a activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol. 2011;186(11):6119–6128. doi: 10.4049/jimmunol.1002843
   PubMed Web of Science ®Google Scholar
• Ather JL, Ckless K, Martin R, et al. Serum amyloid a activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol. 2011;187(1):64–73. doi: 10.4049/jimmunol.1100500
   PubMed Web of Science ®Google Scholar
• Phulphagar K, Kühn LI, Ebner S, et al. Proteomics reveals distinct mechanisms regulating the release of cytokines and alarmins during pyroptosis. Cell Rep. 2021;34(10):108826. doi: 10.1016/j.celrep.2021.108826
   PubMed Web of Science ®Google Scholar
• Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010;107(26):11942–11947. doi: 10.1073/pnas.1003893107
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006;290(3):C917–C924. doi: 10.1152/ajpcell.00401.2005
   PubMed Web of Science ®Google Scholar
• Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174–179. doi: 10.1097/01.shk.0000225404.51320.82
   PubMed Web of Science ®Google Scholar
• Zhu CS, Wang W, Qiang X, et al. Endogenous regulation and pharmacological modulation of sepsis-induced HMGB1 release and action: An updated review. Cells. 2021;10(9):2220. doi: 10.3390/cells10092220
   PubMed Web of Science ®Google Scholar
• Zhu S, Ashok M, Li J, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med. 2009;15(7–8):275–282. doi: 10.2119/molmed.2009.00062
   PubMed Web of Science ®Google Scholar
• Fan J, Li Y, Levy RM, et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol. 2007;178(10):6573–6580. doi: 10.4049/jimmunol.178.10.6573
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7):2652–2660. doi: 10.1182/blood-2002-05-1300
   PubMed Web of Science ®Google Scholar
• Ling Y, Yang ZY, Yin T, et al. Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. Int Immunopharmacol. 2011;11(2):187–193. doi: 10.1016/j.intimp.2010.11.014
   PubMed Web of Science ®Google Scholar
• Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270(43):25752–25761. doi: 10.1074/jbc.270.43.25752
   PubMed Web of Science ®Google Scholar
• Deng M, Tang Y, Li W, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity. 2018;49(4):740–753. doi: 10.1016/j.immuni.2018.08.016
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–496. doi: 10.1038/ni1457.
   PubMed Web of Science ®Google Scholar
• Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462(7269):99–103. doi: 10.1038/nature08512
   PubMed Web of Science ®Google Scholar
• Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007;110(6):1970–1981. doi: 10.1182/blood-2006-09-044776
   PubMed Web of Science ®Google Scholar
• Xu J, Jiang Y, Wang J, et al. Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. Cell Death Differ. 2014;21(8):1229–1239. doi: 10.1038/cdd.2014.40
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukocyte Biol. 2007;81(1):59–66. doi: 10.1189/jlb.0306180
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Bianchi ME, Bacci M, et al. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukocyte Biol. 2007;81(1):84–91. doi: 10.1189/jlb.0306171
   PubMed Web of Science ®Google Scholar
• Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. Embo J. 2007;26(4):1129–1139. doi: 10.1038/sj.emboj.7601552
   PubMed Web of Science ®Google Scholar
• Watanabe H, Son M. The immune tolerance role of the HMGB1-RAGE axis. Cells. 2021;10(3):564. doi: 10.3390/cells10030564
   PubMed Web of Science ®Google Scholar
• Gregoire M, Tadie JM, Uhel F, et al. Frontline science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. J Leukocyte Biol. 2017;101(6):1281–1287. doi: 10.1189/jlb.5HI0316-128RR
   PubMed Web of Science ®Google Scholar
• Patel VS, Sitapara RA, Gore A, et al. HMGB1 mediates hyperoxia-induced impairment of pseudomonas aeruginosa clearance and inflammatory lung injury in mice. Am J Respir Cell Mol Biol. 2013;48(3):280–287. doi: 10.1165/rcmb.2012-0279OC
   PubMed Web of Science ®Google Scholar
• Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101(1):296–301. doi: 10.1073/pnas.2434651100.
   PubMed Web of Science ®Google Scholar
• Liaw PC, Ito T, Iba T, et al. DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev. 2016;30(4):257–261. doi: 10.1016/j.blre.2015.12.004
   PubMed Web of Science ®Google Scholar
• Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importaNCE OF HIGH MOBILITY GROUP BOx protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94(5):975–979. doi: 10.1160/TH05-05-0316
   PubMed Web of Science ®Google Scholar
• Machado FR, Cesar MS. Sepsis, coagulation and anticoagulants. Endocr Metab Immune Disord Drug Targets. 2010;10(3):204–213. doi: 10.2174/187153010791936892
   PubMedGoogle Scholar
• Ito T, Kawahara K, Nakamura T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007;5(1):109–116. doi: 10.1111/j.1538-7836.2006.02255.x
   PubMed Web of Science ®Google Scholar
• Pawlinski R. Platelet HMGB1: the venous clot coordinator. Blood. 2016;128(20):2376–2378. doi: 10.1182/blood-2016-09-738740
   PubMed Web of Science ®Google Scholar
• Lv B, Wang H, Tang Y, et al. High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost. 2009;102(2):352–359. doi: 10.1160/TH08-11-0759
   PubMed Web of Science ®Google Scholar
• Vogel S, Bodenstein R, Chen Q, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest. 2015;125(12):4638–4654. doi: 10.1172/JCI81660
   PubMed Web of Science ®Google Scholar
• Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776–787. doi: 10.1038/nri2402
   PubMed Web of Science ®Google Scholar
• Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 2001;164(10):1768–1773. doi: 10.1164/ajrccm.164.10.2106117
   PubMed Web of Science ®Google Scholar
• Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med. 2006;203(7):1637–1642. doi: 10.1084/jem.20052203
   PubMed Web of Science ®Google Scholar
• Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004;255(3):320–331. doi: 10.1111/j.1365-2796.2003.01302.x
   PubMed Web of Science ®Google Scholar
• Wang H, Zhu S, Zhou R, et al. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med. 2008;10:e32. DOI:10.1017/S1462399408000884
   PubMedGoogle Scholar
• Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock. 2009;32(4):348–357. doi: 10.1097/SHK.0b013e3181a551bd
   PubMed Web of Science ®Google Scholar
• Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115(5):1267–1274. doi: 10.1172/JCI22782.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Levine YA, et al. Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight. 2016;1(7):e85375. doi: 10.1172/jci.insight.85375.
   PubMed Web of Science ®Google Scholar
• Son M, Porat A, He M, et al. C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood. 2016;128(18):2218–2228. doi: 10.1182/blood-2016-05-719757.
   PubMed Web of Science ®Google Scholar
• Chen W, Qiang X, Wang Y, et al. Identification of tetranectin-targeting monoclonal antibodies to treat potentially lethal sepsis. Sci Transl Med. 2020;12(539):12/539. doi: 10.1126/scitranslmed.aaz3833.
   Web of Science ®Google Scholar
• Herzog C, Lorenz A, Gillmann HJ, et al. Thrombomodulin’s lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling. Cardiovasc Res. 2014;101(3):400–410. doi: 10.1093/cvr/cvt275
   PubMed Web of Science ®Google Scholar
• Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007;14(4):431–441. doi: 10.1016/j.chembiol.2007.03.007
   PubMedGoogle Scholar
• Okuma Y, Liu K, Wake H, et al. Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction. Neuropharmacology. 2014;85:18–26. DOI:10.1016/j.neuropharm.2014.05.007
   PubMed Web of Science ®Google Scholar
• Li W, Li J, Sama AE, et al. Carbenoxolone blocks endotoxin-induced Protein Kinase R (PKR) activation and High Mobility Group Box 1 (HMGB1) release. Mol Med. 2013;19(1):203–211. doi: 10.2119/molmed.2013.00064
   PubMedGoogle Scholar
• Li W, Li J, Ashok M, et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol. 2007;178(6):3856–3864. doi: 10.4049/jimmunol.178.6.3856
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li W, Zhu S, et al. Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake. Biochem Pharmacol. 2012;84(11):1492–1500. doi: 10.1016/j.bcp.2012.09.015
   PubMed Web of Science ®Google Scholar
• Takehara K, Murakami T, Kuwahara-Arai K, et al. Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model. Exp Ther Med. 2017;13(6):2969–2974. doi: 10.3892/etm.2017.4308
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H, Andersson U. Targeting Inflammation Driven by HMGB1. Front Immunol. 2020;11:484. doi: 10.3389/fimmu.2020.00484
   PubMed Web of Science ®Google Scholar
• Liu T, Xiang A, Peng T, et al. HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis. Proc Natl Acad Sci U S A. 2019;116(46):23254–23263. doi: 10.1073/pnas.1907490116
   PubMed Web of Science ®Google Scholar
• Li J, Bao G, Wang H. Time to develop therapeutic antibodies against harmless proteins colluding with sepsis mediators? Immunotargets Ther. 2020;9:157–166. doi: 10.2147/ITT.S262605
   PubMed Web of Science ®Google Scholar
• Paterson CW, Ford ML, Coopersmith CM. Breaking the bond between tetranectin and HMGB1 in sepsis. Sci Transl Med. 2020;12(539):12/539. doi: 10.1126/scitranslmed.abb2575
   Web of Science ®Google Scholar
• Crunkhorn S. Antibody intervention rescues mice from sepsis. Nat Rev Drug Discov. 2020;19(6):385–00077. doi: 10.1038/d41573-020-00077-1
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao F, Fang Y, et al. Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response. Crit Care. 2013;17(2):R44. doi: 10.1186/cc12558
   PubMed Web of Science ®Google Scholar
• Kuester D, Lippert H, Roessner A, et al. The cathepsin family and their role in colorectal cancer. Pathol Res Pract. 2008;204(7):491–500. doi: 10.1016/j.prp.2008.04.010
   PubMed Web of Science ®Google Scholar
• Joseph LJ, Chang LC, Stamenkovich D, et al. Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts. J Clin Invest. 1988;81(5):1621–1629. doi: 10.1172/JCI113497.
   PubMed Web of Science ®Google Scholar
• Chauhan SS, Popescu NC, Ray D, et al. Cloning, genomic organization, and chromosomal localization of human cathepsin L. J Biol Chem. 1993;268(2):1039–1045. doi: 10.1016/S0021-9258(18)54038-2
   PubMed Web of Science ®Google Scholar
• McCoy KL, Schwartz RH. The role of intracellular acidification in antigen processing. Immunol Rev. 1988;106(1):129–147. doi: 10.1111/j.1600-065X.1988.tb00777.x
   PubMedGoogle Scholar
• Hsieh CS, deRoos P, Honey K, et al. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol. 2002;168(6):2618–2625. doi: 10.4049/jimmunol.168.6.2618
   PubMed Web of Science ®Google Scholar
• Ishidoh K, Kominami E. Gene regulation and extracellular functions of procathepsin L. Biol Chem. 1998;379(2):131–135. doi: 10.1515/bchm.1998.379.2.131
   PubMed Web of Science ®Google Scholar
• Fiebiger E, Maehr R, Villadangos J, et al. Invariant chain controls the activity of extracellular cathepsin L. J Exp Med. 2002;196(9):1263–1269. doi: 10.1084/jem.20020762.
   PubMed Web of Science ®Google Scholar
• Lemaire R, Huet G, Zerimech F, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol. 1997;36(7):735–743. doi: 10.1093/rheumatology/36.7.735
   PubMedGoogle Scholar
• Lah TT, Hawley M, Rock KL, et al. Gamma-interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophages. FEBS Lett. 1995;363(1–2):85–89. doi: 10.1016/0014-5793(95)00287-J.
   PubMed Web of Science ®Google Scholar
• Kharbanda KK, McVicker DL, Zetterman RK, et al. Ethanol consumption alters trafficking of lysosomal enzymes and affects the processing of procathepsin L in rat liver. Biochim Biophys Acta. 1996;1291(1):45–52. doi: 10.1016/0304-4165(96)00043-8.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ishidoh K, Muno D, et al. Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. Am Rev Respir Dis. 1993;147(6 Pt 1):1562–1568. doi: 10.1164/ajrccm/147.6_Pt_1.1562.
   PubMedGoogle Scholar
• Klose A, Wilbrand-Hennes A, Brinckmann J, et al. Alternate trafficking of cathepsin L in dermal fibroblasts induced by UVA radiation. Exp Dermatol. 2010;19(8):e117–e123. doi: 10.1111/j.1600-0625.2009.01014.x
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Sukhova GK, Sun J, et al. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation. 2007;115(15):2065–2075. doi: 10.1161/CIRCULATIONAHA.107.688523.
   PubMed Web of Science ®Google Scholar
• Schurigt U, Eilenstein R, Gajda M, et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res. 2012;61(9):1021–1029. doi: 10.1007/s00011-012-0495-x.
   PubMed Web of Science ®Google Scholar
• Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59(9):1192–1199. doi: 10.1136/gut.2009.197822
   PubMed Web of Science ®Google Scholar
• Wartmann T, Mayerle J, Kahne T, et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology. 2010;138(2):726–737. doi: 10.1053/j.gastro.2009.10.048.
   PubMed Web of Science ®Google Scholar
• Cai J, Zhong H, Wu J, et al. Cathepsin L promotes vascular intimal hyperplasia after arterial injury. Mol Med. 2017;23(1):92–100. doi: 10.2119/molmed.2016.00222.
   PubMedGoogle Scholar
• Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol. 1990;1(2):127–136.
   PubMedGoogle Scholar
• Heuer JG, Sharma GR, Gerlitz B, et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med. 2004;32(7):1570–1578. doi: 10.1097/01.CCM.0000129488.54282.1A
   PubMed Web of Science ®Google Scholar
• Li W, Ashok M, Li J, et al. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. Plos One. 2007;2(11):e1153. doi: 10.1371/journal.pone.0001153
   PubMed Web of Science ®Google Scholar
• Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49. doi: 10.1186/cc5783
   PubMed Web of Science ®Google Scholar
• Zhou B, Liu J, Zeng L, et al. Extracellular SQSTM1 mediates bacterial septic death in mice through insulin receptor signalling. Nat Microbiol. 2020;5(12):1576–1587. doi: 10.1038/s41564-020-00795-7
   PubMed Web of Science ®Google Scholar
• Machlus KR, Cardenas JC, Church FC, et al. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011;117(18):4953–4963. doi: 10.1182/blood-2010-11-316885
   PubMed Web of Science ®Google Scholar
• Robker RL, Russell DL, Espey LL, et al. Progesterone-regulated genes in the ovulation process: ADAMTS-1 and cathepsin L proteases. Proc Natl Acad Sci U S A. 2000;97(9):4689–4694. doi: 10.1073/pnas.080073497
   PubMed Web of Science ®Google Scholar
• Yanai H, Matsuda A, An J, et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci U S A. 2013;110(51):20699–20704. doi: 10.1073/pnas.1320808110
   PubMed Web of Science ®Google Scholar
• Kang R, Zhang Q, Hou W, et al. Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology. 2014;146(4):1097–1107. doi: 10.1053/j.gastro.2013.12.015
   PubMed Web of Science ®Google Scholar
• Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40:1–116.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhu CS, Qiang X, et al. Development of Procathepsin L (Pcts-L)-inhibiting lanosterol-carrying liposome nanoparticles to treat lethal sepsis. Int J Mol Sci. 2023;24(10):8649. doi: 10.3390/ijms24108649.
   PubMed Web of Science ®Google Scholar
• Buchman TG, Simpson SQ, Sciarretta KL, et al. Sepsis among medicare beneficiaries: 1. The burdens of sepsis, 2012-2018. Crit Care Med. 2020;48(3):276–288. doi: 10.1097/CCM.0000000000004224
   PubMed Web of Science ®Google Scholar
• Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–124. doi: 10.1056/NEJMoa071366
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fisher CJ Jr., Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A sepsis study group. N Engl J Med. 1991;324(7):429–436. doi: 10.1056/NEJM199102143240701
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307(20):1225–1230. doi: 10.1056/NEJM198211113072001
   PubMed Web of Science ®Google Scholar
• Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis study group. JAMA. 1995;273(12):934–941. doi: 10.1001/jama.1995.03520360048038
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269(14):1829–1835. doi: 10.1001/jama.1993.03500140081040
   PubMed Web of Science ®Google Scholar
• Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154–1162. doi: 10.1001/jama.2013.2194
   PubMed Web of Science ®Google Scholar
• Fisher CJ Jr., Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra sepsis syndrome study group. JAMA. 1994;271(23):1836–1843. doi: 10.1001/jama.1994.03510470040032
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327. doi: 10.1097/01.CCM.0000298158.12101.41
   PubMed Web of Science ®Google Scholar
• Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581–614. doi: 10.1016/S1473-3099(15)70112-X
   PubMed Web of Science ®Google Scholar
• Song Y, Shi Y, Ao LH, et al. TLR4 mediates LPS-induced HO-1 expression in mouse liver: role of TNF-alpha and IL-1beta. World J Gastroenterol. 2003;9(8):1799–1803. doi: 10.3748/wjg.v9.i8.1799
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368–1377. doi: 10.1056/NEJMoa010307
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol. 2001;19(1):163–196. doi: 10.1146/annurev.immunol.19.1.163
   PubMedGoogle Scholar
• Wang H, Ward MF, Sama AE. Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets. 2014;18(3):257–268. doi: 10.1517/14728222.2014.863876
   PubMed Web of Science ®Google Scholar
• Vicentino ARR, da Silva Fraga-Junior V, Palazzo M, et al. High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID-19 patients: HMGB1 as a biomarker of worst prognosis. Clin Transl Sci. 2023;16(4):631–646. doi: 10.1111/cts.13475
   PubMed Web of Science ®Google Scholar
• Chen L, Long X, Xu Q, et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020;17(9):992–994. doi: 10.1038/s41423-020-0492-x
   PubMed Web of Science ®Google Scholar
• Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020;26(1):42. doi: 10.1186/s10020-020-00172-4
   PubMed Web of Science ®Google Scholar
• Wei J, Alfajaro MM, DeWeirdt PC, et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell. 2021;184(1):76–91.e13. doi: 10.1016/j.cell.2020.10.028
   PubMed Web of Science ®Google Scholar
• Chen R, Huang Y, Quan J, et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon. 2020;6(12):e05672. doi: 10.1016/j.heliyon.2020.e05672
   PubMed Web of Science ®Google Scholar
• Qiang X, Zhu S, Li J, et al. Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction. J Leukocyte Biol. 2022;22(1):261–267. doi: 10.1002/JLB.3COVCRA0920-628RR
   Google Scholar
• Muus C, Luecken MD, Eraslan G, et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nat Med. 2021;27(3):546–559. doi: 10.1038/s41591-020-01227-z
   PubMed Web of Science ®Google Scholar
• Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6(1):134. doi: 10.1038/s41392-021-00558-8
   PubMed Web of Science ®Google Scholar